Phase I dose-escalation and pharmacokinetic (PK) study of a(6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) in patients with advanced cancers No significant financial relationships ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results